Survivin and Smac gene expressions but not livin are predictors of prognosis in non-small cell lung cancer patients treated with adjuvant chemotherapy following surgery

Japanese Journal of Clinical Oncology

Volumn 40, Issue 4, 2010, Pages 327-335

  Dai, Chun Hua ^a   Li, Jian ^a   Shi, Shun Bing ^a   Yu, Li Chao ^a   Ge, Li Ping ^a   Chen, Ping ^a  

^a AFFILIATED HOSPITAL OF JIANGSU UNIVERSITY   (China)

Author keywords

Livin; Non small cell lung cancer; Prognosis; Smac; Survivin

Indexed keywords

CISPLATIN; GEMCITABINE; LIVIN; LIVIN ALPHA; LIVIN BETA; NAVELBINE; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SURVIVIN; UNCLASSIFIED DRUG; BIRC5 PROTEIN, HUMAN; DIABLO PROTEIN, HUMAN; MESSENGER RNA; MICROTUBULE ASSOCIATED PROTEIN; MITOCHONDRIAL PROTEIN; SIGNAL PEPTIDE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURGERY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; HUMAN; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR DIFFERENTIATION; ADJUVANT CHEMOTHERAPY; BIOSYNTHESIS; GENETICS; KAPLAN MEIER METHOD; LUNG RESECTION; LUNG TUMOR; MIDDLE AGED; MORTALITY;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; FEMALE; GENE EXPRESSION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; MITOCHONDRIAL PROTEINS; PNEUMONECTOMY; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 77951249857     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyp165     Document Type: Article

References (34)

1. Gurubhagavatula S, Lynch TJ. The role of adjuvant chemotherapy for non-small cell lung cancer. Semin Respir Crit Care Med 2005;26:298-303.
2. . The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-60.
3. Winton T, Livinston R, Johnson D, Rigas J, Johnston M, Butts C, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2587-97.
4. Altier DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003;4:46-54.
5. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-21.
6. Fukuda S, Pelus LM. Survivin, a cancer target with an emerging role in normal adult tissue. Mol Cancer Ther 2006;5:1087-98.
7. Kato J, Kuwabara Y, Mitani M, Shinoda N, Sato A, Toyama T, et al. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer 2001;95:92-5.
8. Serela AI, Macadam RC, Farmery SM, Markham AF, Guillou PJ. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 2000;46:645-50.
9. Kajiwara Y, Yamasaki F, Hama S, Yahara K, Yoshioka H, Sugiyama K, et al. Expression of survivin in astrocytic tumor: correlation with malignant grade and prognosis. Cancer 2003;97:1077-83.
10. Shinohara ET, Gonzalez A, Massion PP, Chen H, Li M, Freyer AS, et al. Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma. Cancer 2005;103: 1685-92.
11. Lu B, Gonzalez A, Massion PP, Shyr Y, Shaktour B, Carbone DP, et al. Nuclear survivin as a biomarker for non-small-cell lung cancer. Br J Cancer 2004;91:537-40.
12. Kren L, Brazdil J, Hermanova M, Goncharuk VN, Kallakury BV, Kaur P, et al. Prognostic significance of anti-apoptosis proteins survivin and bel-2 in non-small cell lung carcinoma: a clinicopathologic study of 102 cases. Appl Immunohistochem Mol Morphol 2004;12:44-9.
13. Vischioni B, van der Valk P, Span SW, Kruyt FAE, Rodriguez JA, Giaccone G. Nuclear localization of survivin is a positive prognostic factor for survival in advanced non-small-cell lung cancer. Ann Oncol 2004;15:1654-60.
14. Falleni M, Pellegrini C, Marehetti A, Oprandi B, Buttitta F, Barassi F, et al. Survivin gene expression in early-stage non-small cell lung cancer. J Pathol 2003;200:620-6.
15. Vucic D, Stennicke H, Pisabarro M, Salvesen G, Dixit V. ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr Biol 2000;10:1359-66.
16. Kasof BM, Gomes BC. Livin, a novel inhibitor of apoptosis protein family member. J Biol Chem 2001;276:3238-46.
17. Tanabe H, Yagidashi A, Tsuji N, Shijubo Y, Abe S, Watanabe N. Expression of survivin mRNA and livin mRNA in non-small-cell lung cancer. Lung Cancer 2004;46:299-304.
18. Xiang Y, Yao H, Wang S, Hong M, He J, Cao S, et al. Prognostic value of survivin and livin in nasopharyngeal carcinoma. Laryngoscope 2006;116:126-30.
19. Gazzaniga P, Gradilone A, Giuliani L, Gandini O, Silvestri I, Nofroni I, et al. Expression and prognostic significance of livin, survivin and other apoptosis-related genes in the progression of superficial bladder cancer. Ann Oncol 2003;14:85-90.
20. Kim D-K, Alvarado CS, Abramowsky CR, Gu L, Zhou M, Soe M-M, et al. Expression of inhibitor-of-apoptosis protein (IAP) livin by neuroblastoma cells: correlation with prognostic factors and outcome. Pediatr Dev Pathol 2005;8:621-9.
21. Haferkamp A, Bedke J, Vetter C, Pritsch M, Wagener N, Buse S, et al. High nuclear livin expression is a favourable prognostic indicator in renal cell carcinoma. BJU Int 2008;102:1700-6.
22. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000;102:33-42.
23. Sekimura A, Konishi A, Mizuno K, Kobayashi Y, Sasaki H, Yano M, et al. Expression of Smac/DIABLO is a novel prognostic marker in lung cancer. Oncol Rep 2004;11:797-802.
24. . Mountain CF. Revision in the international system for staging lung cancer. Chest 1997;111:1170-7.
25. Lord RVN, Brabender J, Gandara D, Alaberola V, Camps C, Domine M, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002;8:2286-91.
26. Ceppi P, Volante M, Novello S, Rapa I, Danenbery KD, Danenberg PV, et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 2006;17:1818-25.
27. Monzó M, Rosell R, Felip E, Astudillo J, Sánchez JJ, Maestre J, et al. A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancer. J Clin Oncol 1999;17:2100-4.
28. Zaffaroni N, Pannati M, Collella G, Perego P, Supino R, Gatti L, et al. Expression of the antiapoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci 2002;59: 1406-12.
29. Pennati M, Colella G, Folini M, Citti L, Daidone MG, Zaffaroni N. Ribozyme-mediated attenuation of survivin expression sensitize human melanoma cells to cisplatin-induced apoptosis. J Clin Invest 2002;109:285-6.
30. Kempkensteffen C, Hinz S, Christoph F, Krause H, Koellermann J, Magheli A, et al. Expression of the apoptosis inhibitor livin in renal cell carcinomas: correlations with pathology and outcome. Tumour Biol 2007;28:132-8.
31. Mizutani Y, Nakanishi H, Yamamoto K, Li YN, Matsubara H, Mikami K, et al. Downregulation of smac/DIABLO expression in renal cell carcinoma and its prognostic significance. J Clin Oncol 2005;23:448-54.
32. Espinosa M, Cantu D, Lopez CM, De la Carza JG, Maldonado VA, Melendez-Zajgla J. SMAC is expressed de novo in a subset of cervical cancer tumors. BMC Cancer 2004;4:84.
33. Kempkensteffen C, Jager T, Bub J, Weikert S, Hinz S, Christoph F, et al. The equilibrium of XIAP and Smac/DIABLO expression is gradually deranged during the development and progression of testicular germ cell tumours. Int J Androl 2007;30:476-83.
34. Endo K, Kohnoe S, Watanabe A, Tashiro H, Sakata H, Morita M, et al. Clinical significance of Smac/DIABLO expression in colorectal cancer. Oncol Rep 2009;21:351-5